You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)"拉考沙胺片"獲藥品註冊批件
格隆匯 05-31 17:00

格隆匯5月31日丨石藥集團(01093.HK)宣佈,公司附屬公司石藥集團歐意藥業有限公司開發的拉考沙胺片(100mg()"該產品")已獲得中國國家藥品監督管理局頒發藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。

拉考沙胺選擇性作用於慢失活鈉通道,延長鈉通道失活狀態時間,能夠更加有效地減少鈉離子內流,降低神經元的興奮性,適用於4歲及以上癲癇患者部分性發作的單藥治療和聯合治療。拉考沙胺作為抗癲癇藥物之一,副作用小,不經過肝臟代謝,與其他抗癲癇藥物不會產生有臨牀意義的藥物相互作用,並且由於其獨特的作用機制,可作為部分癲癇發作患者新的治療選擇。

該產品的獲批將進一步豐富集團在神經系統疾病的產品線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account